Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.645 USD | -2.57% | +9.01% | -25.31% |
Financials (USD)
Sales 2024 * | 225M | Sales 2025 * | 321M | Capitalization | 519M |
---|---|---|---|---|---|
Net income 2024 * | -283M | Net income 2025 * | -164M | EV / Sales 2024 * | 2.81 x |
Net Debt 2024 * | 112M | Net Debt 2025 * | 202M | EV / Sales 2025 * | 2.25 x |
P/E ratio 2024 * |
-2.02
x | P/E ratio 2025 * |
-3.62
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on Travere Therapeutics, Inc.
1 day | +1.04% | ||
1 week | +13.67% | ||
Current month | +23.33% | ||
1 month | -2.01% | ||
3 months | -17.83% | ||
6 months | +7.74% | ||
Current year | -24.14% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 19-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 14-07-31 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 22-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 15-03-30 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 14-10-07 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 20-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 6.705 | -1.69% | 397 922 |
24-05-08 | 6.82 | +1.04% | 1,229,505 |
24-05-07 | 6.75 | +3.05% | 1,938,139 |
24-05-06 | 6.55 | +4.63% | 1,383,054 |
24-05-03 | 6.26 | +1.62% | 767,565 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.14% | 519M | |
+2.93% | 108B | |
-2.62% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- TVTX Stock